Cablivi

• Cablivi (caplacizumab) is a targeted therapy for acquired thrombotic thrombocytopenic purpura (aTTP).
• It works by inhibiting the interaction between von Willebrand factor and platelets, reducing clot formation.
• The drug is administered via injection and is typically used in conjunction with plasma exchange and immunosuppression.
• Common side effects include nosebleeds, headaches, and bruising.
• Important warnings relate to an increased risk of bleeding.

What is Cablivi and What is it Used For?

Cablivi (caplacizumab) is a prescription medication primarily used to treat adults with acquired thrombotic thrombocytopenic purpura (aTTP). This rare, life-threatening autoimmune blood disorder is characterized by the formation of numerous small blood clots throughout the body, leading to low platelet counts, red blood cell destruction, and organ damage. The U.S. Food and Drug Administration (FDA) approved Cablivi in 2019 as the first targeted treatment specifically for aTTP, marking a significant advancement in managing this complex condition. Cablivi drug information indicates it is a humanized single-variable domain immunoglobulin (VHH) fragment that targets von Willebrand factor (vWF). It is administered as an intravenous injection followed by daily subcutaneous injections. The treatment aims to stabilize the patient’s condition and reduce the risk of TTP-related complications, often used in conjunction with plasma exchange and immunosuppressive therapy.

• Severe thrombocytopenia (very low platelet count).
• Microangiopathic hemolytic anemia (destruction of red blood cells).
• Organ damage, particularly affecting the brain, kidneys, and heart.

Cablivi Mechanism of Action

The Cablivi mechanism of action involves targeting von Willebrand factor (vWF), a protein crucial for blood clotting. In aTTP, an autoimmune response leads to a deficiency in the ADAMTS13 enzyme, which normally cleaves large vWF multimers. Without proper cleavage, these ultra-large vWF multimers accumulate, becoming hyperactive and spontaneously binding to platelets, causing widespread microvascular thrombosis (small blood clots). Cablivi works by specifically binding to the A1 domain of vWF, preventing its interaction with platelets. By blocking this crucial step in clot formation, Cablivi helps to reduce the incidence of thrombotic events and accelerate platelet count recovery in patients with aTTP. This targeted approach helps to mitigate the severe consequences of uncontrolled clotting associated with the condition.

Cablivi Side Effects and Important Warnings

Like all medications, Cablivi side effects and warnings are important considerations for patients and healthcare providers. The most common side effects reported with Cablivi are generally related to its mechanism of action, which involves inhibiting blood clot formation.

• Nosebleeds (epistaxis)
• Headache
• Gum bleeding
• Bruising
• Urticaria (hives)
• Fatigue

The primary warning associated with Cablivi is an increased risk of bleeding. Patients should be monitored closely for signs and symptoms of bleeding, especially during the initial phase of treatment. It is crucial to inform healthcare providers about any unusual bleeding or bruising. Cablivi should be used with caution in patients with pre-existing bleeding disorders or those taking other medications that affect blood clotting, such as anticoagulants or antiplatelet agents. Patients should avoid elective surgery or other invasive procedures while on Cablivi, or discuss with their doctor if such procedures are necessary, as it may increase the risk of bleeding complications. The safety and efficacy of Cablivi in pediatric patients have not been established.